Abstract
Abstract PSGL-1 may contribute to T cell interaction with the inflamed blood-brain barrier in multiple sclerosis; and therapeutic targeting of PSGL-1 in multiple sclerosis may prove beneficial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
